Genitourinary Cancers

Latest News

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?
How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

September 16th 2025

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.

A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.
IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial Cancer

September 9th 2025

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.
Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

September 5th 2025

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.
Urine Glycosaminoglycan Scores Show High Sensitivity to Detect ccRCC

September 3rd 2025

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

August 18th 2025

Latest CME Events & Activities

More News